Aslan sells Japanese rights to would-be Dupixent rival for $12M

Zenyaku Kogyo is lining up a challenge to Sanofi and Regeneron’s blockbuster Dupixent in Japan, paying Aslan Pharmaceuticals $12 million upfront for local rights to a midphase eczema drug candidate.